Dr. John Cush RheumNow
1 year ago
Fibrosis in IgG4-related disease due to the overexpression of early growth response-1 (EGR-1) by Epithelial cells that facilitates tissue fibrosis https://t.co/PBMqjr0MVV https://t.co/d9b7k2zwYE https://t.co/25aIjIrYm3
Dr. John Cush RheumNow
1 year ago
NHANES, Numbers, & Risk (7.18.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow along with interesting case questions from "Ask Cush Anything".
https://t.co/6DYqAS2rwq https://t.co/7kChNUOx35
On June 27th, 2025, the FDA approved emapalumab for macrophage activation syndrome (MAS) in known or suspected Still’s disease (including both adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)) with inadequate response or intolerance to glucocorticoids.
Dr. John Cush RheumNow
1 year ago
Retrospective review of 457 Autoimmune liver disease pts found 42.5% with Polyautoimmunity. Predictors included ANA positivity (78 vs 47%), ANA titers, dsDNA (12 vs 2%), RF+ (25 vs 9%), disease duration, low albumin, high ESRs. https://t.co/Socl6XWU9a https://t.co/8qomVBh3KP
Dr. John Cush RheumNow
1 year ago
Osteoarthritis (OA) degenerative or inflammatory? 296 pts w/ Knee OA (age 63 yrs, 2/3 had poor oral hygien, K&L grade 2, pain >40). Periodontitis in 62.5% & signif assoc w/ Xray K&L grade 4 (OR 5.39), poor oral hygiene (OR 34), dental visits (OR 8.54), brushing time (OR 21.9) https://t.co/xXIr2qxtt4
Dr. John Cush RheumNow
1 year ago
La Paz study of 903 RA pts; 136 (14.5%) were D2T-RA, 96 for inefficacy. They define early vs Late D2T-RA=44.5 mos, & differed>> Early D2T-RA (1/3) pts more likely to have anxiety or depression (76% v 0), higher CRP @6mos, & time to develop D2TRA (35 vs 70 mos) https://t.co/KFG68y9Uq5
Dr. John Cush RheumNow
1 year ago
Zasocitinib (Tyk2 Inhibitor) Efficacy in Psoriatic Arthritis
A highly selective, tyrosine kinase 2 inhibitor zasocitinib (TAK-279), was studied in a phase 2b trial and found to be effective and safe patients with active psoriatic arthritis (PsA).
https://t.co/HB0eVLLAh6 https://t.co/5Kqopaw6wL
A retrospective Harvard affiliates study shows that rheumatoid arthritis (RA) patients with lung disease have higher mortality, especially respiratory and infection-related mortality than those without lung disease (LD).
Dr. John Cush RheumNow
1 year ago
BMS announced today that the FDA has accepted for review the supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the treatment of adult active psoriatic arthritis. The FDA decision (PDUFA) date is March 6, 2026. https://t.co/yMxkUP5FAw https://t.co/2teEUbWFem
Dr. John Cush RheumNow
1 year ago
Full read overview of new imaging modalities for inflammatory arthritis, including high-res.quantitative CT, ultra-high field MRI), PET, fluorescence optical imaging, optoacoustic imaging, contrast-enhanced ultrasonography - all with artificial intelligence analysis https://t.co/rbHiPWAAFP
Dr. John Cush RheumNow
1 year ago
MTX lowers risk of serious infxn (SI) - UK Observational study of 17 472 newly Dx RA (2018–2023); 10K on MTX, 4,540 other csDMARDs; 13680 corticosteroids (GC). 1307 SI (3/100 PY) w/ reduced adj HR 0.72 (95% CI: 0.63–0.82). 311 SI-related mortality (IR 0.69;0.61–0.77) https://t.co/iuxAivtrYZ
Women exposed to pesticides through farm work or as farmers' wives face increased risk for developing rheumatoid arthritis, a new analysis of Agricultural Health Study data indicated.
Dr. John Cush RheumNow
1 year ago
Manifestations and Treatment in Relapsing Polychondritis
A large multicenter cohort study of Relapsing Polychondritis (RP) describes the clinical manifestations and treatment approaches to this rare, heterogeneous, multisystem disease.
https://t.co/Gz2qwtC4jZ https://t.co/llK9W45DlW
Dr. John Cush RheumNow
1 year ago
“Never be limited by other people's limited imaginations." – Mae Jemison (Physician & first Black woman in space) https://t.co/HwMuaAUVMI
